Diagrammatic recording of head and neck tumours1

The increasing demands of clinical audit have resulted in the need for accurate data collection. The use of tumour maps allows standardization of the records of patients with head and neck cancer, which facilitates collation of data in multicentre studies and makes interdepartmental comparisons more meaningful. The aim of this study was to develop an improved standard set of tumour maps for recording the stage of head and neck tumours. A review of the existing tumour diagrams was performed to identify those anatomical areas that are not adequately represented or where ambiguity exists. The areas where improvements could be made were identified as: (1) the anterior commissure of the larynx; (2) axial and sagittal views of the larynx; (3) the pyriform fossa and cervical oesophagus; (4) the oropharynx and vallecula; (5) the nasal cavity and paranasal sinuses; and (6) cervical nodal involvement. A new set of tumour maps is presented in an attempt to correct some of the limitations of the existing diagrams.     

用COEP方案治疗小细胞未分化肺癌的近期疗效

采用 COEP(CTX、VCR、VP—16、PDN)联合化疗方案治疗小细胞未分化肺癌50例,获 CR 5例(10%)、PR 28例(56%)、RR 33例(66%)。其中初治37例获 CR 2例(5.4%)PR 27例(73%)、RR 29例(78.4%);复治13例获 CR 3例(23.1%)、PR 1例(7.7%)、RR 4例(30.8%),疗效比较满意。     

CO2 laser in cancer surgery of the breast: a comparative clinical study

Review of the literature reveals little to no data regarding the use of the CO2 laser as a surgical modality in the local treatment of breast cancer. This study was undertaken to determine if the CO2 laser is a surgical improvement over the scalpel, influencing patient care during the surgical and postsurgical period. In the author's series, a total of 209 procedures were performed. Within this group, 105 cases were performed with CO2 laser and 104 cases performed with the scalpel. Biopsies were always performed as a separate procedure prior to definitive surgery. This study was not designed to compare cure rates, the medical follow-up period being 1 year. The results of this study demonstrate a significant improvement in patients' postoperative care, surgical technique, and hospital cost-effectiveness.     

Comparison of characteristics of esophageal squamous cell carcinoma associated with head and neck cancer and those with gastric cancer

In ongoing reviews of 339 patients with surgically treated primary squamous cell carcinoma, there were 19 (5.6%) with concurrent gastric cancer and 11 (3.2%) with head and neck cancer. The incidences of intra-esophageal multiple occurrence of esophageal cancer are 27.3% and 26.3% in those with associated head and neck cancer and gastric cancer, respectively, and higher than 7.1% in those without such a concurrent cancer. There was no difference in the clinicopathological characteristics of those with concurrent head and neck and gastric cancers, except for the higher incidence of metachronous occurrence in the former. These findings suggest that, in cases of esophageal cancer associated with concurrent head and neck cancer and gastric cancer, intraesophageal multiplicity of the esophageal carcinoma is frequent and that preoperative serial evaluations is most important to design treatment and estimate the prognosis.     

肺癌患者FLK-1、LRP和MDR1的表达与临床研究

目的:探讨血管内皮生长因子受体 (Flk 1),肺耐药蛋白 (LRP)基因以及多药耐药基因 (MDR1)蛋白与肺癌患者临床及病理指标的关系。方法:用免疫组化技术(ABC法)对原发性肺癌组织中三种基因的表达进行检测。结果: 70例肺癌中,非小细胞肺癌MDR1阳性率 49. 2% (29 /59),明显高于小细胞肺癌 (SCLC) 18. 2% (2 /11)(P<0. 05);非小细胞肺癌LRP阳性率 69. 5% (41 /59),明显高于小细胞肺癌 27. 3% (3 /11) (P<0. 05)。腺癌中MDR1与LRP的表达明显高于鳞癌(P<0. 05)。LRP与Flk 1在NSCLCs中共同表达 49. 2% (29 /59),LRP的表达与肺癌的组织学分级相关,MDR1和LRP的表达与肺癌的组织学类型有关,Flk 1与TNM分期相关,均有统计学意义(P<0. 05)。Flk 1 LRP均阳性、FLK 1 LRP MDR1均阳性、中药治疗、复发与患者的生存率有关(P<0. 05)。结论:FLK 1、LRP和MDR1基因蛋白产物的检测对肺癌患者的诊治和预后评估有积极意义。     

复方金荞麦颗粒治疗肺癌1000例临床疗效观察

目的 总结复方金荞麦颗粒治疗肺癌的疗效。方法 对1000例各种类型的肺癌患者采用复方金荞麦颗粒5g，3次·d^-1 口服，同时辅以中药汤剂治疗，3mo为1疗程，病情稳定后逐渐减量维持。结果本组1000例患者经3mo～15a以上治疗，基本治愈181例（18．1％），显效518例（51．8％），有效204例（20．4％），无效97例（9．7％），总有效率为90．3％。结论 复方金荞麦颗粒为抗肿瘤的纯中药制剂，具有明显抑制肿瘤细胞生长、增强免疫功能、提高患者生存质量等功效，尤其是对失去手术治疗机会、不能接受化疗和放疗的肺癌患者具有较好疗效。     

潘生丁增强氨甲蝶呤的抗肿瘤作用

外源性核苷能抵消抗代谢药对肿瘤细胞的杀伤作用;核苷转运抑制剂潘生丁则能阻断核苷的这种抵消作用,从而增强抗代谢药的细胞毒性。本研究证明,胸苷和次黄嘌呤可明显抵消氨甲蝶呤对L1210细胞的杀伤作用,潘生丁则能有效地阻断核苷的抵消作用;潘生丁和两性霉素B合用可明显增强氨甲蝶呤对小鼠S180肉瘤的抑制作用,但不增强氨甲蝶呤对动物的毒性。提示潘生丁有可能应用于肿瘤联合化疗。     

Evaluating the impact of human papillomavirus vaccines

While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation.